Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 35
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Neural Transm (Vienna) ; 127(9): 1257-1270, 2020 09.
Artículo en Inglés | MEDLINE | ID: mdl-32647923

RESUMEN

Transcranial direct current stimulation (tDCS) has been used to reduce pain in range of chronic pain states. The aim of this review is to evaluate the effectiveness of tDCS on pain reduction and related disability in patients with non-specific chronic low back pain (CLBP). A computer-based systematic literature search was performed in five databases according to PRISMA guidelines. Randomized controlled trials (RCTs) that assessed the effects of tDCS on pain and related disability in patients with non-specific CLBP were included. Modified Jadad scale and Cochrane's risk of bias assessment were used to determine the studies' quality and risk of bias. Meta-analyses were performed by calculating the standardized mean difference (SMD) at 95% confidence interval (CI). Nine RCTs (411 participants) were included in the systematic review according to inclusion criteria, while only five studies could be included in the meta-analysis. The primary motor cortex (M1) was the main stimulated target. The meta-analysis showed non-significant effect of multiple sessions of tDCS over M1 on pain reduction and disability post-treatment respectively, (SMD = 0.378; 95% CI = - 0.264-1.020; P = 0.249), (SMD = 0.143; 95% CI = - 0.214-0.499; P = 0.434). No significant adverse events were reported. The current results do not support the clinical use of tDCS for the reduction of pain and related disability in non-specific CLBP. However, the limited number of available evidence limits our conclusions on the effectiveness of these approaches.


Asunto(s)
Dolor Crónico , Dolor de la Región Lumbar , Corteza Motora , Estimulación Transcraneal de Corriente Directa , Dolor Crónico/terapia , Humanos , Dolor de la Región Lumbar/terapia
2.
Eat Weight Disord ; 25(4): 851-856, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-31062201

RESUMEN

PURPOSE: The aim of this narrative review of the literature was to evaluate and summarize the current literature regarding the effect of lipedema on health-related quality of life (HRQOL) and psychological status. METHODS: The authors collected articles through a search into Medline, Embase, Scopus, Web of Science, Physiotherapy Evidence Database (PEDro), and the Cochrane Review. Search terms used included "Lipoedema," "Lipedema," "psychological status," "Quality of life," "Health related quality of life," and "HRQOL." RESULTS: A total of four observational studies were evaluated. The included studies were moderate-quality according to the Newcastle-Ottawa Scale. Three of the included studies demonstrated deterioration of HRQOL and psychological status in patients with lipedema. These studies also identify that pain and tenderness are a more common and dominant characteristic. CONCLUSION: Future studies should establish a specific approach to treat and manage lipedema symptoms. Based on this narrative review of the literature findings, we recommended for the health care provider to pay more attention to HRQOL and psychological status. Moreover, validated and adapted measures of HRQOL and psychological status for patients with lipedema are required. LEVEL OF EVIDENCE: Level V, narrative review.


Asunto(s)
Lipedema , Calidad de Vida , Humanos
3.
J Neural Transm (Vienna) ; 126(3): 319-325, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30746564

RESUMEN

Evidence suggests that physical activity (PA) exerts beneficial effects on neurodegenerative processes, either as symptomatic relief or disease-modifying strategy. Actually, it may represent a viable neuroprotective intervention in Parkinson's disease dementia (PDD), a severe, frequent, and untreatable complication of Parkinson's disease (PD). According to such hypothesis, this cross-sectional study tested, in PD patients, the association between levels of PA and well-known risk factors for PDD, such as mood disorders and amyloid-ß42 CSF content. Amount of PA was measured by the International Physical Activity Questionnaires-Short Form (IPAQ-SF) in 128 cognitively intact PD patients and correlated with the Hamilton-Depression (HAM-D) and the Hamilton-Anxiety (HAM-A) scores; in a homogenous subgroup of 40 patients, it was further correlated with a panel of CSF biomarkers, including amyloid-ß42, total α-synuclein, total, and phosphorylated tau. The statistical model was corrected for the main potential confounding factors (motor impairment, dopaminergic treatment, disease duration, age, and sex). Both the HAM-A and HAM-D scores, as well as the Aß42 CSF content, improved in parallel with the increase of the total week amount of PA. Although with several limitations, we preliminarily demonstrated that a high level of PA is associated with a more favourable profile of PDD risk factors, in terms of both mood disturbances and CSF markers of neurodegeneration. However, confirmative studies are necessary to validate the efficacy of PA as protective intervention for PDD.


Asunto(s)
Demencia/etiología , Ejercicio Físico/fisiología , Enfermedad de Parkinson/complicaciones , Anciano , Péptidos beta-Amiloides/líquido cefalorraquídeo , Biomarcadores/líquido cefalorraquídeo , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/líquido cefalorraquídeo , Factores de Riesgo , alfa-Sinucleína/líquido cefalorraquídeo , Proteínas tau/líquido cefalorraquídeo
4.
Sensors (Basel) ; 19(24)2019 Dec 11.
Artículo en Inglés | MEDLINE | ID: mdl-31835822

RESUMEN

Currently, clinical evaluation represents the primary outcome measure in Parkinson's disease (PD). However, clinical evaluation may underscore some subtle motor impairments, hidden from the visual inspection of examiners. Technology-based objective measures are more frequently utilized to assess motor performance and objectively measure motor dysfunction. Gait and balance impairments, frequent complications in later disease stages, are poorly responsive to classic dopamine-replacement therapy. Although recent findings suggest that transcranial direct current stimulation (tDCS) can have a role in improving motor skills, there is scarce evidence for this, especially considering the difficulty to objectively assess motor function. Therefore, we used wearable electronics to measure motor abilities, and further evaluated the gait and balance features of 10 PD patients, before and (three days and one month) after the tDCS. To assess patients' abilities, we adopted six motor tasks, obtaining 72 meaningful motor features. According to the obtained results, wearable electronics demonstrated to be a valuable tool to measure the treatment response. Meanwhile the improvements from tDCS on gait and balance abilities of PD patients demonstrated to be generally partial and selective.


Asunto(s)
Marcha/fisiología , Enfermedad de Parkinson/terapia , Equilibrio Postural/fisiología , Dispositivos Electrónicos Vestibles , Anciano , Anciano de 80 o más Años , Femenino , Marcha/efectos de la radiación , Humanos , Masculino , Actividad Motora/fisiología , Actividad Motora/efectos de la radiación , Enfermedad de Parkinson/fisiopatología , Enfermedad de Parkinson/rehabilitación , Equilibrio Postural/efectos de la radiación , Estimulación Transcraneal de Corriente Directa/métodos
5.
J Neural Transm (Vienna) ; 124(9): 1105-1108, 2017 09.
Artículo en Inglés | MEDLINE | ID: mdl-28620833

RESUMEN

Low levels of serum uric acid (UA) are a risk factor for many neurodegenerative diseases but the role of UA in tauopathies has not been yet fully evaluated. In this study, we assessed the risk associated with serum UA levels in a large group of patients with tauopathies, either primary or secondary. The mean serum UA concentrations of 111 patients with tauopathies (TAU), including 41 with progressive supranuclear palsy (PSP), 45 with Alzheimer's disease (AD) and 25 with frontotemporal dementia (FTD) were compared to that of 130 controls (CTL). The association between serum UA and TAU condition, PSP, AD and FTD was calculated as odd ratio (OR) adjusted for age and gender. A cut-off value of serum UA was finally obtained to predict subjects at risk for TAU. The serum UA levels in TAU and PSP, AD and FTD subgroups were similar, and significantly lower than CTL. Linear regression revealed inverse relationships between UA and TAU (OR = 0.610), PSP (OR = 0.626), AD (OR = 0.685) and FTD (OR = 0.577). The cut-off value of 4.35 mg/dl (AUC = 0.655) discriminates TAU from CTL, although with poor specificity and sensitivity. Low concentrations of serum UA represent a common risk factor for different tauopathies (PSP, FTD and AD). These findings may represent a starting point for preventive strategies or novel therapeutic approaches in this group of severe neurodegenerative diseases.


Asunto(s)
Enfermedad de Alzheimer/sangre , Demencia Frontotemporal/sangre , Parálisis Supranuclear Progresiva/sangre , Ácido Úrico/sangre , Anciano , Biomarcadores/sangre , Femenino , Humanos , Masculino , Curva ROC , Estudios Retrospectivos , Factores de Riesgo
12.
J Clin Med ; 11(19)2022 Oct 05.
Artículo en Inglés | MEDLINE | ID: mdl-36233749

RESUMEN

BACKGROUND: Sleep disturbances are common among athletes. There is recently a growing interest in improving sleep quality by using noninvasive brain stimulation techniques such as transcranial direct current stimulation (tDCS). We hypothesized that bilateral dorsolateral prefrontal cortex anodal tDCS could improve sleep in different sports athletes. A randomized controlled trial is to be conducted to test this hypothesis. METHODS: Eighty-four athletes are selected based on specific eligibility criteria and randomly allocated to the intervention or control group. Each participant will receive a 20-min session of bilateral anodal tDCS with an intensity of 1.5 mA (0.057 mA/cm2) in density 3 times a week for 2 weeks. The tDCS current will be delivered only for 30 seconds in the control group. This study's outcome is a set of subjective and objective sleep parameters. CONCLUSION: This study assessed the effect of a novel tDCS protocol represented by bilateral anodal stimulation and may result in important advances in sleep management among athletes. Because of the high incidence and impact of athletes' poor sleep quality, it is particularly important to explore effective interventions. TRIAL REGISTRATION: ClinicalTrials.gov: NCT05318352.

13.
NPJ Parkinsons Dis ; 7(1): 82, 2021 Sep 17.
Artículo en Inglés | MEDLINE | ID: mdl-34535672

RESUMEN

Early noninvasive reliable biomarkers are among the major unmet needs in Parkinson's disease (PD) to monitor therapy response and disease progression. Objective measures of motor performances could allow phenotyping of subtle, undetectable, early stage motor impairments of PD patients. This work aims at identifying prognostic biomarkers in newly diagnosed PD patients and quantifying therapy-response. Forty de novo PD patients underwent clinical and technology-based kinematic assessments performing motor tasks (MDS-UPDRS part III) to assess tremor, bradykinesia, gait, and postural stability (T0). A visit after 6 months (T1) and a clinical and kinematic assessment after 12 months (T2) where scheduled. A clinical follow-up was provided between 30 and 36 months after the diagnosis (T3). We performed an ANOVA for repeated measures to compare patients' kinematic features at baseline and at T2 to assess therapy response. Pearson correlation test was run between baseline kinematic features and UPDRS III score variation between T0 and T3, to select candidate kinematic prognostic biomarkers. A multiple linear regression model was created to predict the long-term motor outcome using T0 kinematic measures. All motor tasks significantly improved after the dopamine replacement therapy. A significant correlation was found between UPDRS scores variation and some baseline bradykinesia (toe tapping amplitude decrement, p = 0.009) and gait features (velocity of arms and legs, sit-to-stand time, p = 0.007; p = 0.009; p = 0.01, respectively). A linear regression model including four baseline kinematic features could significantly predict the motor outcome (p = 0.000214). Technology-based objective measures represent possible early and reproducible therapy-response and prognostic biomarkers.

14.
Parkinsonism Relat Disord ; 90: 62-64, 2021 09.
Artículo en Inglés | MEDLINE | ID: mdl-34392132

RESUMEN

We measured α-Klotho in CSF and serum of PD patients at early stage of the disease, finding two distinct pools, the first increased, the second reduced. CSF α-Klotho was inversely associated with CSF α-synuclein levels. Our preliminary results suggest α-Klotho as potential biomarker or therapeutic target in PD.


Asunto(s)
Proteínas Klotho/análisis , Enfermedad de Parkinson/sangre , Enfermedad de Parkinson/líquido cefalorraquídeo , Biomarcadores/sangre , Biomarcadores/líquido cefalorraquídeo , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Persona de Mediana Edad , alfa-Sinucleína/líquido cefalorraquídeo
15.
Clin Neurol Neurosurg ; 198: 106242, 2020 11.
Artículo en Inglés | MEDLINE | ID: mdl-32979681

RESUMEN

Pisa syndrome (PS) is a postural deformity characterized by marked and reversible lateral trunk flexion. PS can be seen in Parkinson's disease (PD) and several neurodegenerative diseases. A scoping systematic review was conducted to view the therapeutic interventions for PS in PD, their effectiveness, outcome measurements, and related cofactors. Databases and manual searches were performed. Studies that evaluate the effect of interventions on PS were included. Data were extracted and categorized by the main applied therapeutic intervention. A total of 19 published and 2 unpublished studies met the inclusion criteria. Wall and traditional goniometer, kinematic analysis, and clinical observations were used to detect PS. The included studies applied the following therapeutic protocols: Deep brain stimulation (DBS), Botulinum toxin injection, posture exercises, lidocaine injection, oculomotor correction, and spinal cord stimulation. The outcomes measurements of the included studies were linked to International Classification of Functioning, Disability and Health (ICF) model. The therapeutic interventions variously improve PS outcomes at short and long-term follow-up. The interventions did not report side effects or adverse events except DBS. PS severity was related to the DBS voltage amount in one study, and one participant in another study relapsed due to DBS. There are missing reported data in terms of participants' characteristics, medication status, and side effects. The current evidence shows the available interventions for PS, outcomes measurements, and related cofactors. The interventions may be safe and beneficial for PS. Further powerful studies are required.


Asunto(s)
Atrofia Muscular Espinal/etiología , Atrofia Muscular Espinal/terapia , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/terapia , Postura , Ensayos Clínicos como Asunto/métodos , Estimulación Encefálica Profunda/métodos , Terapia por Ejercicio/métodos , Humanos , Osteopatía/métodos , Enfermedad de Parkinson/diagnóstico , Postura/fisiología , Estimulación de la Médula Espinal/métodos , Síndrome
16.
J Alzheimers Dis ; 76(3): 1171-1178, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32597810

RESUMEN

BACKGROUND: Synaptopathy is critical in pathophysiology of Parkinson's disease (PD). Cerebrospinal fluid (CSF) levels of neurogranin (NG) and amyloid-ß42 (Aß42) are considered markers of synaptic dysfunction in neurodegenerative diseases. OBJECTIVE: To evaluate the CSF synaptopathy-related biomarkers, especially the novel Aß42/NG ratio, in PD, establishing possible associations with cognitive level and other clinical parameters. METHODS: Levels of NG, Aß42, amyloid-ß40, total and phosphorylated tau, and Aß42/NG ratio were measured in 30 PD patients and 30 controls and correlated with cognitive and motor parameters. The accuracy in distinguishing the cognitive status was determined. RESULTS: NG and Aß42 were significantly reduced in PD, with higher NG levels in patients with worse cognition. The Aß42/NG ratio showed a direct correlation with Mini-Mental State Examination, independently from age and sex, and differentiated cognitively impaired patients with 92% sensitivity and 71.4% specificity, accuracy higher than NG alone. No correlations resulted with motor disturbances or therapy. CONCLUSIONS: The novel Aß42/NG ratio couples either presynaptic or postsynaptic markers of synaptic dysfunction, representing a potential global index of synaptopathy, useful to track cognitive functions in PD.


Asunto(s)
Péptidos beta-Amiloides/líquido cefalorraquídeo , Disfunción Cognitiva/líquido cefalorraquídeo , Neurogranina/líquido cefalorraquídeo , Enfermedad de Parkinson/líquido cefalorraquídeo , Anciano , Enfermedad de Alzheimer/líquido cefalorraquídeo , Enfermedad de Alzheimer/complicaciones , Péptidos beta-Amiloides/metabolismo , Biomarcadores/líquido cefalorraquídeo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/complicaciones , Fragmentos de Péptidos/líquido cefalorraquídeo , Proteínas tau/líquido cefalorraquídeo
17.
Mov Disord Clin Pract ; 7(7): 797-802, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32837960

RESUMEN

Background: COVID-19 outbreak profoundly affected health systems and people's daily life worldwide. Parkinson's disease (PD) patients lost their normal routine and interrupted regular physical activity, either as physiotherapy or sport, with inevitable consequence on their daily-life and well-being. Objectives: To evaluate the changes in physical activity due to COVID-19 emergency, including self-management strategies or technology-assisted activities, and the subsequent clinical implications in PD patients. Methods: Seventy-four patients from an Italian center have been remotely examined during the lockdown (April-May 2020) by an e-mail structured survey, including self-administered scales. We collected and analyzed data on changes, modalities and amount of physical active practice, on the use of technology-based tools, and on self-perceived clinical condition. Results: Sixty percent of patients reported a significant worsening of their general conditions during the lockdown, the reduction of physical activity being the main risk factor for such change. However, patients found ways to practice physical activity, using satisfactorily technology assistance in 50% of cases (mostly women). Conclusions: The COVID-19 emergency has been an ordeal for PD patients. Nevertheless, patients adapted their habits to continue practicing physical activity that resulted a main determinant of their well-being; as well, they successfully approached technology-based assistance. Education, communication, and networking emerge as critical for a constructive reaction to the emergency's challenges.

18.
J Exerc Rehabil ; 15(2): 187-192, 2019 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-31110999

RESUMEN

The aim of this review was to evaluate, summarize and discuss the available literature concerning the effect of robot-assisted gait training (RAGT) on patient with Parkinson disease (PD) and freezing of gait (FOG). A comprehensive literature search was conducted utilizing of MEDLINE, Embase, Scopus, Web of Science, PEDro (Physiotherapy Evidence Database), and the Cochrane Review. Search terms used in-cluded 'Parkinson disease,' 'Freezing of gait,' 'RAGT,' 'robot-assisted gait training,' 'Locomotor rehabilitation,' 'gait trainer,' and 'robotics assisted gait training.' A total of 4 studies were evaluated, but these studies were primarily of low-level evidence. All the 4 studies noted positive outcomes with using RAGT on FOG. No adverse events or side effects that occurred during and/or after the interventions. While the current literature generally offers support for the use of RAGT for FOG treatment, there is a paucity of strong evidence to support its widespread use. The increasing availability of RAGT technology offers the potential for engaging therapy in FOG rehabilitation, but its utility remains uncertain given the limited studies available at this time.

19.
NeuroRehabilitation ; 44(1): 79-84, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30741700

RESUMEN

BACKGROUND: Trunk alignment is thought to contribute to neck function. However, this common assumption is not clear in patients with Parkinson's disease (PwPD) suffering from different postural deformities such as: Pisa syndrome (PS), Camptocormia & Antecollis (C&A). OBJECTIVES: to investigate the effect of different postural deformities including PS and C&A on neck function and pain in patient (PwPD). METHODS: Forty-five participants belonging to three groups: 15 PD patients without postural disorders (PD), 15 with PS, and 15 with C&A. The function, disability and pain were assessed by Neck Disability Index (NDI), and Brief Pain Inventory (BPI) which used to assess the pain severity (BPI-PS) and Pain Interference (BPI-PI). All groups completed clinical assessments by the Unified Parkinson's Disease Rating Scale (UPDRS), Modified Hoenh & Yahr (mH&Y) staging and the Levodopa Equivalent Daily Dose (LEDD). RESULTS: PD group compared with PS and C&A groups showed differences in NDI, BPI-PS, BPI-PI, LEDD and mH&Y staging (P < 0.001), but no differences found in PD duration, UPDRS-II and III in the same groups. Moreover, no differences were observed between PS and C&A groups in the mentioned scales. DISCUSSION AND CONCLUSION: These results demonstrated that PS and C&A are associated with severe impairment of neck functions, and pain in PwPD.


Asunto(s)
Dolor de Cuello/fisiopatología , Enfermedad de Parkinson/fisiopatología , Equilibrio Postural/fisiología , Anciano , Anciano de 80 o más Años , Estudios Transversales , Personas con Discapacidad , Femenino , Humanos , Levodopa/uso terapéutico , Masculino , Persona de Mediana Edad , Atrofia Muscular Espinal/tratamiento farmacológico , Atrofia Muscular Espinal/epidemiología , Atrofia Muscular Espinal/fisiopatología , Dolor de Cuello/diagnóstico , Dolor de Cuello/epidemiología , Dolor/tratamiento farmacológico , Dolor/epidemiología , Dolor/fisiopatología , Enfermedad de Parkinson/tratamiento farmacológico , Enfermedad de Parkinson/epidemiología , Proyectos Piloto , Curvaturas de la Columna Vertebral/tratamiento farmacológico , Curvaturas de la Columna Vertebral/epidemiología , Curvaturas de la Columna Vertebral/fisiopatología
20.
NeuroRehabilitation ; 44(3): 419-424, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31177242

RESUMEN

BACKGROUND: Postural deformities, such as Pisa syndrome (PS), and camptocormia and antecollis (C&A) are common in patient with Parkinson's disease (PwPD). These deformities can lead to back disability and pain with different mechanisms, including abnormal loading or stress on soft tissues as muscles, lumbar discs and ligaments. OBJECTIVES: To evaluate the effect of different postural deformities including PS and C&A on back function and pain in PwPD. METHODS: The function, disability and pain were assessed by Oswestry disability index (ODI) and brief pain inventory (BPI). All participants completed clinical assessments by the Unified Parkinson's Disease Rating Scale (UPDRS), Modified Hoenh & Yahr (mH&Y) staging and the Levodopa Equivalent Daily Dose (LEDD). RESULTS: PS and C&A groups significantly showed worse disability ODI and pain BPI, and higher LEDD and mH&Y stage compared with PD groups. However, no differences were found in PD duration and UPDRS in the same groups. Moreover, no differences were observed between PS and C&A groups in the mentioned scales. CONCLUSION: These results demonstrated that PS and C&A are associated with severe impairment of back functions and pain. Rehabilitation programs for PwPD and PS, and C&A should include spine alignment and postural training.


Asunto(s)
Dolor de Espalda/fisiopatología , Atrofia Muscular Espinal/fisiopatología , Enfermedad de Parkinson/fisiopatología , Postura/fisiología , Curvaturas de la Columna Vertebral/fisiopatología , Anciano , Anciano de 80 o más Años , Dolor de Espalda/diagnóstico , Dolor de Espalda/epidemiología , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Atrofia Muscular Espinal/diagnóstico , Atrofia Muscular Espinal/epidemiología , Dimensión del Dolor/métodos , Enfermedad de Parkinson/diagnóstico , Enfermedad de Parkinson/epidemiología , Curvaturas de la Columna Vertebral/diagnóstico , Curvaturas de la Columna Vertebral/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA